WEBULL
WebtradeDownload

Is Ocular Therapeutix (OCUL) Cheap On FDA Alignment For AXPAXLI?

Simply Wall St · 2d ago

Ocular Therapeutix (OCUL) is back in focus after management confirmed a successful Pre-New Drug Application meeting with the FDA for AXPAXLI for wet age-related macular degeneration, with an NDA filing still targeted for late 2026.

Recent trading has cooled enthusiasm, with the share price down 4.94% over the past day and 10.38% over the week. Ocular Therapeutix still shows a 5.71% 90 day share price return and a very large 3 year total shareholder return of roughly 3x. This suggests that momentum has moderated in the short term after a strong multi year run as investors reassess risk and expectations around AXPAXLI’s path to market.

Scan how Ocular Therapeutix compares with other eye care and biotech players that could be setting up for their own rerating by checking our hand picked 16 high quality undiscovered gems

Bulls point to Ocular Therapeutix’s FDA alignment and AXPAXLI data, while bears focus on recent share price weakness and heavy losses. As you weigh the risk and reward, which side does the current valuation lean toward?

Most Popular Narrative: 62% Undervalued

Ocular Therapeutix last closed at $10.19, against a widely followed fair value estimate of $27.09 per share, so the key question is how AXPAXLI and the balance of risks justify that gap under a 7.24% discount rate.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

See why 9 investors see Ocular Therapeutix as 62% undervalued.

Result: Fair Value of $27.09 (UNDERVALUED)

Still, the whole Ocular Therapeutix story leans heavily on AXPAXLI. As a result, any clinical stumble or slower than expected real world uptake could quickly challenge that undervalued thesis.

Find out about the key risks to this Ocular Therapeutix narrative.

Another View: Ocular Therapeutix On Sales Ratios

The first story on Ocular Therapeutix leans heavily on a big gap to fair value. On simple sales metrics the picture is very different. The stock trades on a P/S of 43x, compared with 5.3x for the US Pharmaceuticals group and 1.2x for close peers, while the fair ratio points to just 0.1x. That kind of spread raises the question of how much execution risk is already baked into the current price.

To see how that stacks up against detailed ratio work and what the numbers imply for valuation risk, See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:OCUL P/S Ratio as at Sep 2026
NasdaqGM:OCUL P/S Ratio as at Sep 2026

Next Steps

Sentiment on Ocular Therapeutix is clearly split. Move quickly, review the data on both the risks and the potential upside, then weigh the 2 key rewards and 3 important warning signs.

Looking for more Ocular Therapeutix investment ideas?

Do not stop your research with Ocular Therapeutix alone. Broaden your watchlist with a few focused screens that surface different types of opportunities investors often overlook.

  • Target potential mispricings by scanning a curated set of companies that combine quality fundamentals with attractive valuations through the 34 high quality undervalued stocks.
  • Reduce portfolio stress by concentrating on resilient businesses that carry lower measured risk scores using the focused 11 resilient stocks with low risk scores.
  • Strengthen your income stream by zeroing in on shares offering higher yields that aim to sustain their payouts through the 6 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.